Evolution of Thromboelastography During Tranexamic Acid Treatment

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jan 10, 2019

Keywords

ClinConnect Summary

Patients with hematological malignancies often develop low platelet counts either as a consequence of the disease or the treatment by chemotherapy or stem cell transplantation. Platelet transfusions are commonly given to raise any low platelet count and reduce the risk of clinical bleeding (prophylaxis) or stop active bleeding (therapy). The last studies have showed that many patients continue to experience bleeding, despite the use of platelet transfusions. Tranexamic acid is an antifibrinolytic agent. It reduces the breakdown of clots formed. This treatment is widely used in medicine (e.g...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient affiliated to a social security regimen or beneficiary of the same
• • Signed written informed consent form
• • Confirmed diagnosis of a hematological malignancy and undergoing intensive chemotherapy
• • Expected to experience hypoproliferative thrombocytopenia resulting in a platelet count of ≤10 G/L for ≥ 5 days
• Exclusion Criteria:
• • Pregnant women
• • Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
• • Refractoriness to platelet transfusion or requirement for a specific type of platelet transfusion (ABO-compatible, plasma-free)
• • Ongoing anticoagulant therapy or antiplatelet therapy at the time of enrolment
• • Treatment with any pro-coagulant agent within 48 hours of enrolment, or enrolment in other trials involving platelet transfusions, platelet growth factors, or presentation of a known hypercoagulable state
• • Diagnosis of arterial or venous thromboembolic disease within the previous year
• • Patient experiencing a bleeding event WHO grade ≥ 2 within 7 days before inclusion
• • contra-indications to tranexamic acid (allergy, history of seizures, creatinine clearance \< 30 mL/min)
• • Refusing participation